New York, USA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Myasthenia Gravis Market is Projected to Boost at a Moderate Growth Rate by 2032, Estimates DelveInsight | Leading Companies - DAS-MG, Catalyst, Cabaletta Bio, Janssen, Argenx, UCB Pharma, Alexion, Immunovant
The dynamics of the myasthenia gravis market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies.
DelveInsight’s Myasthenia Gravis Market Insights report includes a comprehensive understanding of current treatment practices, myasthenia gravis emerging drugs, market share of individual therapies, and current and forecasted myasthenia gravis market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Myasthenia Gravis Market Report
- As per DelveInsight’s analysis, the myasthenia gravis market is anticipated to grow at a significant CAGR by 2032.
- As per DelveInsight estimates, the total number of diagnosed prevalent cases of generalized myasthenia gravis associated in the 7MM countries was approximately 116K in 2021.
- Leading myasthenia gravis companies such as DAS-MG, Inc, Catalyst Pharmaceuticals, Inc., Cabaletta Bio, Janssen Research & Development, LLC, Argenx, UCB Pharma, Alexion, Immunovant Sciences GmbH, Cartesian Therapeutics, Ra Pharmaceuticals, Inc., and others are developing novel myasthenia gravis drugs that can be available in the myasthenia gravis market in the coming years.
- Some of the key therapies for myasthenia gravis treatment include DAS-001, Amifampridine Phosphate, MuSK-CAART, Nipocalimab, Efgartigimod IV, Rozanolixizumab, ALXN1720, Batoclimab, Descartes-08, Zilucoplan (RA101495), and others.
Discover which therapies are expected to grab the major myasthenia gravis market share @ Myasthenia Gravis Market Report
Myasthenia Gravis Overview
Myasthenia gravis is a chronic autoimmune disorder that affects the neuromuscular junction, leading to muscle weakness and fatigue. This condition arises when the body’s immune system mistakenly attacks the receptors responsible for receiving nerve signals in the muscles, impairing their ability to contract properly. The exact cause of myasthenia gravis remains unknown, but it is believed to involve a combination of genetic and environmental factors. It is not directly inherited, but a family history of the condition can increase the risk.
The hallmark symptom of myasthenia gravis is muscle weakness, which tends to worsen with activity and improve with rest. Common myasthenia gravis symptoms include drooping eyelids, double vision, difficulty in swallowing, slurred speech, and weakness in the arms and legs. Symptoms can vary widely among individuals and can also fluctuate, making diagnosis and management challenging. Diagnosing myasthenia gravis can be challenging, as its symptoms can mimic other conditions. Physicians typically start with a detailed medical history and a physical examination. Specialized tests, such as electromyography (EMG) and nerve conduction studies, can help confirm the presence of neuromuscular dysfunction.
Myasthenia Gravis Epidemiology Segmentation
The myasthenia gravis epidemiology section provides insights into the historical and current myasthenia gravis patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The myasthenia gravis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Generalized Myasthenia Gravis Diagnosed Prevalent Cases
- Generalized Myasthenia Gravis Gender-Specific Cases
- Generalized Myasthenia Gravis Antibodies-Specific Cases
Download the report to understand which factors are driving myasthenia gravis epidemiology trends @ Myasthenia Gravis Epidemiological Insights
Myasthenia Gravis Treatment Market
The treatment of myasthenia gravis typically involves a multi-faceted approach aimed at managing its symptoms and improving the patient’s quality of life. The cornerstone of myasthenia gravis treatment is the use of medications, most commonly acetylcholinesterase inhibitors like pyridostigmine, which enhance communication between nerve and muscle cells. Immunosuppressive drugs, such as corticosteroids, azathioprine, or mycophenolate mofetil, may also be prescribed to reduce the immune system’s attack on the neuromuscular junction.
In more severe cases or during myasthenia gravis crises, where symptoms become life-threatening, treatments like intravenous immunoglobulin (IVIG) or plasmapheresis may be employed to rapidly suppress the immune response. Additionally, some patients benefit from surgical interventions, such as thymectomy, to remove the thymus gland, which is often implicated in myasthenia gravis. It’s essential for myasthenia gravis patients to work closely with healthcare professionals to tailor their treatment plans to their specific needs, as responses to medications and therapies can vary significantly among individuals. Regular follow-up appointments and adjustments to treatment are typically necessary to effectively manage this chronic autoimmune disorder.
Learn more about the FDA-approved drugs for myasthenia gravis @ Drugs for Myasthenia Gravis Treatment
Key Myasthenia Gravis Therapies and Companies
- DAS-001: DAS-MG, Inc
- Amifampridine Phosphate: Catalyst Pharmaceuticals, Inc.
- MuSK-CAART: Cabaletta Bio
- Nipocalimab: Janssen Research & Development, LLC
- Efgartigimod IV: argenx
- Rozanolixizumab: UCB Pharma
- ALXN1720: Alexion
- Batoclimab: Immunovant Sciences GmbH
- Descartes-08: Cartesian Therapeutics
- Zilucoplan (RA101495): Ra Pharmaceuticals, Inc.
To know more about clinical trials, visit @ Myasthenia Gravis Treatment Drugs
Myasthenia Gravis Market Dynamics
The myasthenia gravis market dynamics have undergone significant changes in recent years. Several key factors shape the dynamics of the myasthenia gravis market. Firstly, increased awareness and improved diagnostic methods have led to a growing number of myasthenia gravis cases being identified. This has expanded the patient pool, driving the demand for myasthenia gravis treatments and therapies. Secondly, the pharmaceutical industry has responded to this demand with ongoing research and development efforts to create more effective and targeted therapies for MG. The introduction of novel drugs and biologics has brought new hope to myasthenia gravis patients, providing a more diverse range of treatment options.
Thirdly, the competitive landscape of the myasthenia gravis market has intensified. Pharmaceutical companies are striving to gain a competitive edge through innovation, pricing strategies, and market access. This competition has the potential to drive both innovation and affordability for myasthenia gravis treatments. Lastly, patient advocacy groups and support organizations have become influential in driving awareness and research funding for myasthenia gravis. They contribute to shaping the myasthenia gravis market dynamics by pushing for improved treatment options and patient-centric approaches.
However, several factors may impede the growth of the myasthenia gravis market. Despite advancements, myasthenia gravis still lacks a definitive cure. This limitation in treatment options poses a significant barrier to both patients and pharmaceutical companies aiming to develop more effective therapies. The development of new myasthenia gravis treatments is a costly and time-consuming process. High research and development costs can deter smaller pharmaceutical companies from entering the myasthenia gravis market, limiting innovation.
Stringent regulatory requirements for drug approval can slow down the introduction of new myasthenia gravis treatments. The need for extensive clinical trials and regulatory approvals can be a barrier to timely access for patients. Many myasthenia gravis patients face challenges in accessing specialized healthcare and treatments. The cost of myasthenia gravis therapies can be prohibitive, especially for those without adequate insurance coverage or financial resources.
| Myasthenia Gravis Report Metrics | Details |
| Study Period | 2019–2032 |
| Myasthenia Gravis Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Key Myasthenia Gravis Companies | DAS-MG, Inc, Catalyst Pharmaceuticals, Inc., Cabaletta Bio, Janssen Research & Development, LLC, Argenx, UCB Pharma, Alexion, Immunovant Sciences GmbH, Cartesian Therapeutics, Ra Pharmaceuticals, Inc., and others |
| Key Myasthenia Gravis Therapies | DAS-001, Amifampridine Phosphate, MuSK-CAART, Nipocalimab, Efgartigimod IV, Rozanolixizumab, ALXN1720, Batoclimab, Descartes-08, Zilucoplan (RA101495), and others |
Scope of the Myasthenia Gravis Market Report
- Therapeutic Assessment: Myasthenia Gravis current marketed and emerging therapies
- Myasthenia Gravis Market Dynamics: Attribute Analysis of Emerging Myasthenia Gravis Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Myasthenia Gravis Market Access and Reimbursement
Discover more about myasthenia gravis drugs in development @ Myasthenia Gravis Clinical Trials
Table of Contents
| 1. | Myasthenia Gravis Market Key Insights |
| 2. | Myasthenia Gravis Market Report Introduction |
| 3. | Myasthenia Gravis Market Overview at a Glance |
| 4. | Myasthenia Gravis Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Myasthenia Gravis Treatment and Management |
| 7. | Myasthenia Gravis Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Myasthenia Gravis Marketed Drugs |
| 10. | Myasthenia Gravis Emerging Drugs |
| 11. | Seven Major Myasthenia Gravis Market Analysis |
| 12. | Myasthenia Gravis Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Myasthenia Gravis Epidemiology Forecast
Myasthenia Gravis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted myasthenia gravis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Myasthenia Gravis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including Viela Bio, UCB Pharma, Momenta Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Hoffmann-La Roche, Alexion Pharmaceuticals, Catalyst Pharmaceuticals, Harbour BioMed, Novartis, Takeda, DAS Therapeutics, RemeGen, Cartesian Therapeutics, Nanjing IASO Biotherapeutics, Cabaletta Bio, CytoDyn, Ahead Therapeutics, Toleranzia, Rallybio, among others.
Generalized Myasthenia Gravis Pipeline
Generalized Myasthenia Gravis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key generalized myasthenia gravis companies, including Biocon, Cartesian Therapeutics, UCB, Momenta Pharmaceuticals, HanAll Biopharma, Roche, Alexion, Novartis, Takeda, BioMarin, among others.
Generalized Myasthenia Gravis Market
Generalized Myasthenia Gravis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key generalized myasthenia gravis companies, including UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., among others.
Generalized Myasthenia Gravis Epidemiology
Generalized Myasthenia Gravis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted generalized myasthenia gravis epidemiology in the 7MM.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
